KIT and neoplasm: Due to uncertainty about upfront surgical resectability, the patient was started on imatinib (400 mg/day), a tyrosine kinase inhibitor (TKI) that blocks the constitutively active receptor tyrosine kinase c-KIT, to induce adequate tumor response for potential surgical resection with negative margins [3–5].